Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
49 hedge funds and large institutions have $24.7M invested in Mersana Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 22 reducing their positions, and 39 closing their positions.
61.32% more ownership
Funds ownership: 2.48% → 63.81% (+61%)
8% more capital invested
Capital invested by funds: $22.9M → $24.7M (+$1.77M)
23% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 22
41% less funds holding
Funds holding: 83 → 49 (-34)
87% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AV
Alamea Verwaltungs
Edison,
New Jersey
|
+$3.05M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$492K |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$359K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$350K |
| 5 |
Morgan Stanley
New York
|
+$255K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.19M |
| 2 |
CCM
Catalio Capital Management
New York
|
-$464K |
| 3 |
Goldman Sachs
New York
|
-$424K |
| 4 |
BlackRock
New York
|
-$408K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$395K |
MRSN Hedge Fund Activity: Q3 2025 in Review
49 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q3 2025, worth a combined $24.7M — up 7.7% from $22.9M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of MRSN and 5 opened new positions — a net loss of 34 holders — while 22 trimmed existing stakes and 17 added.
The largest buyer was Alamea Verwaltungs, adding an estimated $3.05M. The largest seller was AQR Capital Management, cutting an estimated $1.19M.
- 49 institutional investors held Mersana Therapeutics (MRSN) as of Q3 2025, down from 83 in Q2 2025.
- Funds reported $24.7M of Mersana Therapeutics stock for Q3 2025, up 7.7% quarter-over-quarter.
- 5 funds opened new Mersana Therapeutics positions in Q3 2025 and 39 closed out, a net change of -34 holders.
- The largest Mersana Therapeutics buyer in Q3 2025 was Alamea Verwaltungs, an estimated $3.05M added.
- The largest Mersana Therapeutics seller in Q3 2025 was AQR Capital Management, an estimated $1.19M sold.
Based on aggregated 13F filings for Q3 2025.